GLP3 – Reta (10mg) | Research Peptide

Retatrutide is an investigational 39-amino-acid, fatty-acid-acylated triple agonist engineered to engage the GIP, GLP-1, and glucagon receptors from a single peptide backbone. Phase 2 trial cohorts and supporting preclinical work have characterised its receptor pharmacology, gastric-emptying effects, and observed changes in body composition and hepatic-fat endpoints in obesity and MASLD research populations. Reported phase 1b and phase 2 data describe dose-ranging pharmacokinetic and pharmacodynamic profiles, while structural biology studies have begun to map its binding mode across the three class B GPCRs. Discussed here strictly as an investigational research compound; MP supplies retatrutide for in vitro and non-clinical laboratory study only. For laboratory and research use only.